BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
3 clinical-grade skincare creams you really shouldn’t buy online 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Moderna (NASDAQ: MRNA) has received approval from the U.S. Food and Drug Administration (FDA) for its mRNA-based influenza vaccine, mFLUSIVA, for adults aged 50 and older. The approval marks a significant milestone for the biotechnology company, making mFLUSIVA its first approved mRNA flu vaccine and its fourth FDA-approved product in the United States. Globally, the vaccine becomes Moderna's fifth approved product.
The company plans to begin shipping mFLUSIVA to select retailers across the United States in the coming weeks, allowing availability ahead of the 2026–2027 respiratory virus season.
The FDA's decision follows a unanimous recommendation from the Vaccines and Related Biological Products Advisory Committee and is supported by results from a Phase 3 clinical trial involving 40,805 adults aged 50 years and older across 11 countries. The study demonstrated the vaccine's effectiveness while maintaining an acceptable safety profile, with researchers reporting no new safety concerns.
For adults aged 65 and above, the vaccine received accelerated approval based on immune response data from a separate U.S. trial that enrolled 2,992 participants. Moderna said it will conduct post-marketing confirmatory studies to further verify the vaccine's clinical benefits for this older age group, as required under the accelerated approval pathway.
Moderna CEO Stephane Bancel said the company's mRNA technology expands vaccination options for older adults, who face a higher risk of severe influenza and related complications. The company believes its mRNA platform can help improve protection against seasonal flu while supporting broader innovation in vaccine development.
Beyond the U.S., Moderna is seeking to expand the vaccine's global reach. Regulatory applications for mFLUSIVA are currently under review in the European Union, Canada, and Australia, with additional submissions planned later this year. If approved in these markets, the vaccine could strengthen Moderna's growing respiratory vaccine portfolio and reinforce its position in the global influenza vaccine market.
